MEG4 Antibody

What is MEG4 and why is it important in research?

MEG4 refers to two distinct proteins that should not be confused:

• A plant protein in Zea mays (maize) - the primary target of most commercial MEG4 antibodies

• A synonym sometimes used for YME1L1 (ATP-dependent zinc metalloprotease) in human research

The maize MEG4 protein (UniProt: Q6JB12) is studied in plant developmental biology, while the human protein YME1L1 (sometimes called MEG4, UniProt: Q96TA2) plays critical roles in mitochondrial protein metabolism, maintaining cristae morphology, and protecting mitochondria from oxidatively damaged membrane proteins . When ordering or working with MEG4 antibodies, researchers must verify which protein target is relevant to their research.

How do I distinguish between antibodies targeting plant MEG4 versus human YME1L1/MEG4?

To avoid confusion between plant MEG4 and human YME1L1 (sometimes called MEG4):

• Verify the UniProt number:

  • Plant MEG4: Q6JB12

  • Human YME1L1: Q96TA2

• Check the immunogen information:

  • Plant MEG4 antibodies typically use "Recombinant Zea mays (Maize) MEG4 protein" as immunogen

  • Human YME1L1 antibodies typically use human recombinant protein fragments as immunogen

• Examine species reactivity:

  • Plant MEG4 antibodies react with Zea mays (maize)

  • Human YME1L1 antibodies react with human, and sometimes mouse, rat, or other mammalian samples

What applications are MEG4 antibodies validated for?

The primary plant MEG4 antibody (CSB-PA910931XA01ZAX) has been validated for:

• ELISA (Enzyme-Linked Immunosorbent Assay)

• WB (Western Blot)

For human YME1L1/MEG4 antibodies, validated applications typically include:

• Western Blotting (WB)

• Immunohistochemistry (IHC)

• ELISA

• Some are also validated for Flow Cytometry (FACS) and Immunofluorescence (IF)

Always check the specific validation data for your antibody of interest, as validation varies between manufacturers and product codes.

What is the recommended protocol for using MEG4 antibody in Western blotting applications?

For plant MEG4 antibody in Western blotting:

• Sample preparation:

  • Extract total protein from plant tissue using standard extraction buffer

  • Denature samples at 95°C for 5 minutes in loading buffer containing SDS and β-mercaptoethanol

• Electrophoresis and transfer:

  • Run 10-20 μg protein per lane on 10-12% SDS-PAGE

  • Transfer to PVDF or nitrocellulose membrane

• Antibody incubation:

  • Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

  • Dilute primary MEG4 antibody 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3x with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG)

  • Develop using chemiluminescence reagents

• Controls:

  • Include recombinant MEG4 protein as a positive control when available

  • Include a pre-immune serum control to assess specificity

For human YME1L1/MEG4 antibodies, a similar protocol applies but with recommended dilution typically between 1:1000-1:5000 .

How can I optimize ELISA protocols using MEG4 antibody?

For optimizing ELISA with MEG4 antibody:

• Coating conditions:

  • Use carbonate/bicarbonate buffer (pH 9.6) for coating the plate

  • For direct ELISA, coat with target antigen at 1-10 μg/mL

  • For sandwich ELISA, coat with capture antibody (typically 1-5 μg/mL)

• Blocking and detection:

  • Block with 1-5% BSA or non-fat milk in PBS with 0.05% Tween-20

  • For detection, dilute MEG4 antibody according to manufacturer's recommendation, typically starting at 1:400 and perform a titration

  • For enzymatic detection, alkaline phosphatase or HRP-conjugated secondary antibodies are commonly used

• Optimization steps:

  • Perform checkerboard titration to determine optimal antibody concentrations

  • Test different blocking agents (BSA vs. milk protein)

  • Optimize incubation times and temperatures

  • Include appropriate positive and negative controls

What are the best practices for storage and handling of MEG4 antibody to maintain activity?

For optimal MEG4 antibody storage and handling:

• Storage conditions:

  • Store antibody at -20°C or -80°C according to manufacturer specifications

  • Avoid repeated freeze-thaw cycles which can degrade antibody activity

  • For plant MEG4 antibody, the recommended storage buffer contains 50% glycerol and 0.03% Proclin 300 in PBS, pH 7.4

• Working solutions:

  • For working dilutions, use freshly prepared buffer

  • Keep antibody on ice during experiment setup

  • Return to appropriate storage immediately after use

• Aliquoting:

  • Upon receipt, divide antibody into small working aliquots

  • Document the number of freeze-thaw cycles on each tube

  • Consider adding carrier protein (BSA) to dilute solutions if not already present

• Quality control:

  • Periodically test antibody performance with positive controls

  • Monitor for signs of activity loss or increased background

How does antibody affinity impact experimental results when working with MEG4 antibody?

Antibody affinity significantly impacts experimental outcomes with MEG4 antibody:

• Trade-offs between affinity and specificity:

  • High-affinity antibodies may provide stronger signals but can sometimes show reduced specificity

  • Research has shown that improvements in antibody affinity can sometimes lead to deficits in other properties, like stability

• Key affinity determinants:

  • CDR sequence composition significantly affects specificity

  • The presence of arginine in CDRs increases risk of non-specific interactions

  • Serine residues in CDRs can mediate high-affinity binding while maintaining specificity

• Experimental implications:

  • For low-abundance targets, higher affinity antibodies may be necessary

  • For applications requiring high specificity (e.g., immunohistochemistry), moderate affinity antibodies with higher specificity might be preferable

  • Consider using blocking peptides to confirm specificity in critical experiments

• Affinity measurement:

  • Equilibrium dissociation constant (Kd) values below 10⁻⁸ M typically indicate high affinity

  • Surface plasmon resonance (SPR) can be used to measure antibody-antigen kinetics

What approaches can be used to validate antibody specificity for MEG4 in complex samples?

To validate MEG4 antibody specificity in complex samples:

• Multiple detection methods:

  • Confirm target recognition using more than one technique (e.g., Western blot, immunoprecipitation, immunofluorescence)

  • Look for consistent molecular weight and localization patterns

• Genetic validation:

  • Test antibody in knockout/knockdown systems (when available)

  • Compare antibody staining patterns in samples with known expression levels

• Peptide competition:

  • Pre-incubate antibody with excess immunizing peptide/protein

  • Specific signals should be blocked while non-specific signals remain

  • For plant MEG4 antibody, use recombinant Zea mays MEG4 protein for competition assays

• Mass spectrometry validation:

  • Immunoprecipitate target protein and confirm identity by mass spectrometry

  • This technique can identify both the target protein and potential cross-reacting proteins

• Orthogonal antibodies:

  • Compare results with antibodies raised against different epitopes of the same protein

  • Concordant results increase confidence in specificity

What are the critical considerations when using MEG4 antibody for studying protein-protein interactions?

When using MEG4 antibody for protein interaction studies:

• Epitope accessibility concerns:

  • Binding partners may mask antibody epitopes

  • Use antibodies targeting different regions of MEG4 to avoid interference

  • Consider native versus denaturing conditions based on experiment goals

• Antibody interference:

  • The antibody itself may disrupt protein-protein interactions

  • Perform control experiments to assess whether antibody binding affects complex formation

  • Consider crosslinking approaches to stabilize complexes before antibody application

• Co-immunoprecipitation optimization:

  • Optimize buffer conditions (salt concentration, detergents, pH)

  • Test both stringent and mild lysis conditions

  • Include appropriate negative controls (non-specific IgG, pre-immune serum)

  • Consider proximity ligation assays as an alternative method

• Quantification approaches:

  • Use appropriate quantification methods to assess interaction strength

  • Consider transfected tagged versions of proteins for verification

  • Implement FRET or BiFC methods as orthogonal approaches

How can I resolve high background issues when using MEG4 antibody in immunoassays?

To address high background with MEG4 antibody:

• Blocking optimization:

  • Test different blocking reagents (BSA, casein, commercial blockers)

  • Increase blocking time or concentration

  • Add 0.1-0.3% Triton X-100 or Tween-20 to reduce hydrophobic interactions

• Antibody dilution:

  • Further dilute primary and secondary antibodies

  • Titrate to determine optimal concentration balancing signal and background

  • For plant MEG4 antibody, try starting at 1:1000 dilution and adjust as needed

• Washing protocols:

  • Increase number and duration of wash steps

  • Use higher salt concentration in wash buffers (up to 500 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffers

• Sample preparation:

  • Pre-clear lysates with Protein A/G beads to remove proteins that bind non-specifically

  • Pre-absorb antibody with proteins from a negative control sample

• Controls to implement:

  • Include secondary-only controls

  • Use pre-immune serum at the same concentration as primary antibody

  • Include isotype controls to identify Fc-mediated binding

What are the potential causes of false positive or false negative results when using MEG4 antibody?

Potential causes of false results with MEG4 antibody:

False Positives:

• Cross-reactivity:

  • Antibody may recognize similar epitopes on unrelated proteins

  • Check sequence homology of target epitope with other proteins

  • Perform peptide competition assays to confirm specificity

• Non-specific binding:

  • Fc receptor interactions in certain cell types

  • Hydrophobic interactions with denatured proteins

  • Use appropriate blocking and Fc receptor blocking reagents

• Detection system issues:

  • Endogenous peroxidase or phosphatase activity

  • Biotin in samples if using biotin-based detection

  • Include enzyme inhibition steps and appropriate controls

False Negatives:

• Epitope masking:

  • Post-translational modifications may interfere with antibody binding

  • Protein-protein interactions may hide epitopes

  • Test different extraction/fixation methods

• Low target abundance:

  • Implement signal amplification methods

  • Concentrate samples before analysis

  • Consider more sensitive detection systems

• Technical factors:

  • Antibody degradation

  • Inappropriate fixation affecting epitope structure

  • Use fresh antibody aliquots and optimize fixation protocols

How do antibody-based versus nucleic acid-based methods compare for studying MEG4 expression?

Comparison of methods for studying MEG4 expression:

For comprehensive MEG4 expression studies, combining both approaches provides complementary data on transcription and translation, offering insights into potential post-transcriptional regulation.

How do the performance characteristics of polyclonal versus monoclonal MEG4 antibodies compare in research applications?

Performance comparison of polyclonal versus monoclonal MEG4 antibodies:

Currently, most commercially available MEG4 antibodies are polyclonal preparations, including the standard plant MEG4 antibody (CSB-PA910931XA01ZAX) from Cusabio, which is a rabbit polyclonal antibody purified using antigen affinity chromatography .

What special considerations exist when using MEG4 antibody in different model organisms?

Species-specific considerations for MEG4 antibody applications:

• Plant systems (e.g., Zea mays):

  • The CSB-PA910931XA01ZAX antibody is specifically raised against maize MEG4

  • May not cross-react with MEG4 homologs in other plant species

  • Background autofluorescence from plant tissues can interfere with immunofluorescence

  • Cell wall components may limit accessibility in some applications

• Human/mammalian research (YME1L1/MEG4):

  • Ensure you're using an antibody against human YME1L1 (sometimes called MEG4)

  • Check for species cross-reactivity if working with model organisms

  • Human YME1L1 antibodies may need different extraction protocols to maintain mitochondrial protein integrity

  • Consider mitochondrial fractionation for enrichment of target protein

• Cross-species reactivity:

  • Always validate antibodies in your specific species of interest

  • Sequence conservation analysis can help predict potential cross-reactivity

  • Epitope mapping can identify species-specific variations that may affect binding

• Expression considerations:

  • Plant MEG4 may have tissue-specific expression patterns

  • Human YME1L1 is broadly expressed but with tissue-specific abundance differences

  • Consider appropriate positive and negative control tissues

What role might MEG4/YME1L1 antibodies play in understanding mitochondrial disease mechanisms?

MEG4/YME1L1 antibodies in mitochondrial disease research:

• Functional investigation:

  • YME1L1 ensures cell proliferation and maintains normal cristae morphology

  • It promotes antiapoptotic activity and protects mitochondria from accumulating oxidatively damaged membrane proteins

  • Controls the accumulation of non-assembled respiratory chain subunits (NDUFB6, OX4, and ND1)

  • Antibodies can help quantify expression changes in disease states

• Disease associations:

  • YME1L1 dysfunction has been linked to mitochondrial encephalopathy

  • Its role in processing OPA1 connects it to optic atrophy mechanisms

  • Antibodies can be used to assess expression and localization in patient samples

• Methodological applications:

  • Immunoprecipitation to identify disease-specific interaction partners

  • Antibody-based proteomics to map expression changes in disease tissues

  • Immunohistochemistry to assess cellular and subcellular distribution changes

• Therapeutic development:

  • Antibodies as tools to validate therapeutic targets affecting YME1L1 function

  • Assessment of therapeutic effects on YME1L1 expression and activity

  • Development of proximity-based assays to screen for compounds affecting YME1L1 interactions

What are the emerging applications of MEG4 antibodies in advanced research techniques?

Emerging applications for MEG4 antibodies:

• Proximity labeling techniques:

  • APEX2 or BioID fusion with YME1L1/MEG4 for proximity proteomics

  • Anti-MEG4 antibodies for validation of proximity labeling results

  • Identification of transient interaction partners in mitochondrial quality control

• Super-resolution microscopy:

  • Antibody conjugation with photoswitchable fluorophores for STORM/PALM

  • Dual-color super-resolution to map nanoscale organization within mitochondria

  • Combination with mitochondrial markers to assess cristae organization

• Single-cell applications:

  • Antibody-based single-cell proteomics (CyTOF, CITE-seq)

  • Correlation of MEG4/YME1L1 expression with mitochondrial function at single-cell level

  • Spatial transcriptomics combined with antibody staining for tissue organization studies

• High-throughput screening:

  • Automated immunofluorescence in drug screening applications

  • Phenotypic screens using MEG4/YME1L1 localization or expression as readouts

  • CRISPR screens with antibody-based detection of YME1L1 function

• Intrabody applications:

  • Development of intracellularly expressed antibody fragments for live-cell studies

  • Monitoring protein dynamics in real-time

  • Targeted protein knockdown using antibody-based degraders

How might advances in antibody engineering improve future MEG4 antibody performance?

Future antibody engineering advances for MEG4 research:

• Recombinant antibody technologies:

  • Conversion of polyclonal antibodies to defined recombinant antibodies

  • Single B-cell sequencing to identify high-affinity clones

  • Phage display selection for improved specificity

  • Detailed workflow processes typically involve assessment of cell line activity, cell culture optimization, purification, quality control, and specialized shipping

• Fragment-based improvements:

  • Development of single-chain variable fragments (scFvs) for improved tissue penetration

  • Nanobody development for smaller size and novel epitope access

  • Bi-specific antibodies to simultaneously detect MEG4 and interaction partners

• Conjugation technologies:

  • Site-specific conjugation to maintain antibody orientation

  • Novel reporter systems with improved signal-to-noise ratio

  • Multiplexed detection through spectral unmixing or DNA barcoding

• Affinity and specificity engineering:

  • CDR optimization to reduce non-specific binding

  • Research shows careful selection of CDR composition (avoiding excess arginine, incorporating serine) can greatly improve specificity

  • Humanization for therapeutic applications

  • Affinity maturation while preserving specificity

• Production improvements:

  • Standardized antibody characterization (epitope mapping, cross-reactivity profiling)

  • Enhanced expression systems for difficult antibodies

  • Improved formulation for longer shelf-life and activity maintenance